FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796723390> ?p ?o ?g. }

• W2796723390 endingPage "321" @default.
• W2796723390 startingPage "314" @default.
• W2796723390 abstract "Pencil-beam scanning intensity modulated proton therapy (IMPT) may allow for an improvement in the therapeutic ratio compared with conventional techniques of radiation therapy delivery for pancreatic cancer. The purpose of this study was to describe the clinical implementation of IMPT for intact and clinically localized pancreatic cancer, perform a matched dosimetric comparison with volumetric modulated arc therapy (VMAT), and report acute adverse event (AE) rates and patient-reported outcomes (PROs) of health-related quality of life.Between July 2016 and March 2017, 13 patients with localized pancreatic cancer underwent concurrent capecitabine or 5-fluorouracil-based chemoradiation therapy (CRT) utilizing IMPT to a dose of 50 Gy (radiobiological effectiveness: 1.1). A VMAT plan was generated for each patient to use for dosimetric comparison. Patients were assessed prospectively for AEs and completed PRO questionnaires utilizing the Functional Assessment of Cancer Therapy-Hepatobiliary at baseline and upon completion of CRT.There was no difference in mean target coverage between IMPT and VMAT (P > .05). IMPT offered significant reductions in dose to organs at risk, including the small bowel, duodenum, stomach, large bowel, liver, and kidneys (P < .05). All patients completed treatment without radiation therapy breaks. The median weight loss during treatment was 1.6 kg (range, 0.1-5.7 kg). No patients experienced grade ≥3 treatment-related AEs. The median Functional Assessment of Cancer Therapy-Hepatobiliary scores prior to versus at the end of CRT were 142 (range, 113-163) versus 136 (range, 107-173; P = .18).Pencil-beam scanning IMPT was feasible and offered significant reductions in radiation exposure to multiple gastrointestinal organs at risk. IMPT was associated with no grade ≥3 gastrointestinal AEs and no change in baseline PROs, but the conclusions are limited due to the patient sample size. Further clinical studies are warranted to evaluate whether these dosimetric advantages translate into clinically meaningful benefits." @default.
• W2796723390 created "2018-04-24" @default.
• W2796723390 creator A5012698810 @default.
• W2796723390 creator A5030581430 @default.
• W2796723390 creator A5033323953 @default.
• W2796723390 creator A5050766065 @default.
• W2796723390 creator A5052777541 @default.
• W2796723390 creator A5071942279 @default.
• W2796723390 creator A5074277192 @default.
• W2796723390 creator A5083871900 @default.
• W2796723390 creator A5088854603 @default.
• W2796723390 date "2018-07-01" @default.
• W2796723390 modified "2023-09-26" @default.
• W2796723390 title "Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes" @default.
• W2796723390 cites W1894182878 @default.
• W2796723390 cites W1965097611 @default.
• W2796723390 cites W1972373303 @default.
• W2796723390 cites W1975718149 @default.
• W2796723390 cites W1980367758 @default.
• W2796723390 cites W1999946563 @default.
• W2796723390 cites W2016236483 @default.
• W2796723390 cites W2024003240 @default.
• W2796723390 cites W2025905881 @default.
• W2796723390 cites W2026191784 @default.
• W2796723390 cites W2026511819 @default.
• W2796723390 cites W2032457799 @default.
• W2796723390 cites W2035281362 @default.
• W2796723390 cites W2046043778 @default.
• W2796723390 cites W2046422578 @default.
• W2796723390 cites W2054541588 @default.
• W2796723390 cites W2060636261 @default.
• W2796723390 cites W2062292984 @default.
• W2796723390 cites W2071442044 @default.
• W2796723390 cites W2079833923 @default.
• W2796723390 cites W2103711657 @default.
• W2796723390 cites W2130409622 @default.
• W2796723390 cites W2151253787 @default.
• W2796723390 cites W2165480504 @default.
• W2796723390 cites W2172089182 @default.
• W2796723390 cites W2196287118 @default.
• W2796723390 cites W2271118059 @default.
• W2796723390 cites W2313049478 @default.
• W2796723390 cites W2346921980 @default.
• W2796723390 cites W3124937987 @default.
• W2796723390 doi "https://doi.org/10.1016/j.adro.2018.04.003" @default.
• W2796723390 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6128024" @default.
• W2796723390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30202800" @default.
• W2796723390 hasPublicationYear "2018" @default.
• W2796723390 type Work @default.
• W2796723390 sameAs 2796723390 @default.
• W2796723390 citedByCount "19" @default.
• W2796723390 countsByYear W27967233902018 @default.
• W2796723390 countsByYear W27967233902019 @default.
• W2796723390 countsByYear W27967233902020 @default.
• W2796723390 countsByYear W27967233902021 @default.
• W2796723390 countsByYear W27967233902022 @default.
• W2796723390 countsByYear W27967233902023 @default.
• W2796723390 crossrefType "journal-article" @default.
• W2796723390 hasAuthorship W2796723390A5012698810 @default.
• W2796723390 hasAuthorship W2796723390A5030581430 @default.
• W2796723390 hasAuthorship W2796723390A5033323953 @default.
• W2796723390 hasAuthorship W2796723390A5050766065 @default.
• W2796723390 hasAuthorship W2796723390A5052777541 @default.
• W2796723390 hasAuthorship W2796723390A5071942279 @default.
• W2796723390 hasAuthorship W2796723390A5074277192 @default.
• W2796723390 hasAuthorship W2796723390A5083871900 @default.
• W2796723390 hasAuthorship W2796723390A5088854603 @default.
• W2796723390 hasBestOaLocation W27967233901 @default.
• W2796723390 hasConcept C121608353 @default.
• W2796723390 hasConcept C126322002 @default.
• W2796723390 hasConcept C126838900 @default.
• W2796723390 hasConcept C197934379 @default.
• W2796723390 hasConcept C2777909004 @default.
• W2796723390 hasConcept C2779244869 @default.
• W2796723390 hasConcept C2780210213 @default.
• W2796723390 hasConcept C2989005 @default.
• W2796723390 hasConcept C509974204 @default.
• W2796723390 hasConcept C526805850 @default.
• W2796723390 hasConcept C71924100 @default.
• W2796723390 hasConceptScore W2796723390C121608353 @default.
• W2796723390 hasConceptScore W2796723390C126322002 @default.
• W2796723390 hasConceptScore W2796723390C126838900 @default.
• W2796723390 hasConceptScore W2796723390C197934379 @default.
• W2796723390 hasConceptScore W2796723390C2777909004 @default.
• W2796723390 hasConceptScore W2796723390C2779244869 @default.
• W2796723390 hasConceptScore W2796723390C2780210213 @default.
• W2796723390 hasConceptScore W2796723390C2989005 @default.
• W2796723390 hasConceptScore W2796723390C509974204 @default.
• W2796723390 hasConceptScore W2796723390C526805850 @default.
• W2796723390 hasConceptScore W2796723390C71924100 @default.
• W2796723390 hasIssue "3" @default.
• W2796723390 hasLocation W27967233901 @default.
• W2796723390 hasLocation W27967233902 @default.
• W2796723390 hasLocation W27967233903 @default.
• W2796723390 hasLocation W27967233904 @default.
• W2796723390 hasLocation W27967233905 @default.
• W2796723390 hasOpenAccess W2796723390 @default.
• W2796723390 hasPrimaryLocation W27967233901 @default.

• next